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Abstract: To evaluate the impact of mutations at reverse transcriptase codon 135 on treatment outcomes in patients re-
ceiving NNRTI-based antiretroviral therapy, a total of 68 patients (30 with and 38 without baseline mutations at codon 
135) were evaluated. Median increases in CD4 counts were 135 and 90 cells/mm
3 (p=0.32), virologic suppression (HIV 
RNA < 400 copies/mL) was achieved in 16 (53%) and 16 (42%) patients (p=0.50), while NNRTI resistance was detected 
in 10/14 (71%) and 16/22 (73%) in patients with and without mutations at codon 135, respectively. Patients who experi-
enced a virologic breakthrough and had a baseline mutation at codon 135 were more likely to evolve a single NNRTI re-
sistance mutation (8/14 vs 4/22, p=0.029) but less likely to evolve multiple NNRTI resistance mutations (2/14 vs 12/22, p 
= 0.033). Mutations at codon 135 do not affect response rates, but affect the pattern of development of NNRTI resistance 
mutations. This has important implications for the subsequent use of newer NNRTIs such as etravirine in salvage therapy. 
INTRODUCTION 
  The use of highly active antiretroviral therapy (HAART) 
has proven remarkably effective in controlling the progres-
sion of HIV/AIDS and prolonging survival, but these bene-
fits can be compromised by the development of drug resis-
tance. Recent estimates
 of the prevalence of drug resistance 
during the first years
 of widespread use of potent antiretrovi-
ral therapy have indicated
 that about 70% of treated adults 
with detectable viremia have isolates with drug resistance 
mutations [1, 2].  Clinically significant
  resistance to some 
drugs, notably non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs), can emerge after just a brief exposure
 to this 
class of medications. A single point
  mutation, such as the 
K103N, is sufficient to cause high-level NNRTI resistance to 
all currently available agents in this class [3]. The majority 
of NNRTI resistance can be accounted for by the presence of 
recognized mutations in the reverse transcriptase (RT) gene. 
However,  certain additional polymorphisms present in dif-
ferent settings may result in decreased drug susceptibility. In 
individuals with such polymorphisms who were never 
treated with NNRTIs, phenotypic analysis has revealed evi-
dence of measurable decreases in drug susceptibility [4]. 
  A number of reports have suggested that mutations at RT 
codon 135 (I to one of T/M/V/L/R/K) may impact NNRTI 
susceptibility. In vitro, a 2.5-fold increase in IC50 to nevirap-
ine or delavirdine [5] and to nevirapine or efavirenz [6] was 
observed in the absence of any prior drug exposure. Some 
databases list the I135T mutation as being associated with 
NNRTI resistance [7]. More recently, genetic changes at   
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codon 135 were associated with the subsequent accumula-
tion of mutations in subjects receiving an NNRTI-containing 
regimen, indicating that such mutations may provide an al-
ternate route for the development of high-grade NNRTI drug 
resistance [8]. Other reports; however, have not identified 
such a relationship [9]. 
  Over the past several years we have developed a success-
ful program for the treatment of HIV-infected injection drug 
users (IDUs) within a directly observed therapy (DOT) pro-
gram using simplified treatment regimens [10, 11]. In our 
IDU drug naive population, we have detected mutations at 
RT codon 135 (mainly 135T) in more than 40% of cases 
[12]. These mutations occurring at such a high frequency 
may have a significant impact on response rates to NNRTIs 
and their use in clinical practice. With this in mind, we 
sought to evaluate the CD4 cell counts and plasma viral load 
responses to NNRTI-based regimens as well as the evolution 
of nucleoside reverse transcriptase inhibitor (NRTI) and 
NNRTI resistance mutations in patients with or without mu-
tations at codon 135 prior to the initiation of therapy. 
MATERIALS AND METHODOLOGY 
  HIV-infected IDUs with pre- and post-treatment geno-
typic resistance testing who received NNRTIs for the first 
time and for more than 1 month were included in this retro-
spective study. HAART regimens were received through a 
DOT program at the Pender Community Health Centre, a 
multidisciplinary clinic located on the downtown east side of 
Vancouver, Canada. HAART regimens were individualized, 
based on considerations of efficacy and toxicity with regi-
mens being mainly based on nevirapine or efavirenz along 
with two NRTIs. 
  CD4 cell counts and HIV plasma viral load responses to 
NNRTI-based therapy were compared in patients with or 
without mutations at RT codon 135 at baseline. HIV plasma 
viral load was measured using the Amplicor HIV-1 Moni-Clinical Implications of Mutations at Codon 135  The Open Virology Journal, 2007, Volume 1    9 
tor
™ assay (Roche Diagnostics, Mississauga, ON). Plasma 
viral load was defined as below the limit of quantitation if it 
was <400 HIV RNA copies/mL. Immunologic response was 
monitored using the CD4 cell count, measured by flow cy-
tometry at the local reference laboratory. HIV plasma viral 
load and CD4 cell counts were measured at baseline, and at 
approximately three month intervals or more frequently if 
clinically indicated. Efficacy was evaluated based on the 
most recent HIV plasma viral load and CD4 cell count 
measurements or the last one prior to a change in therapy if 
applicable. Baseline data were also collected on patient 
demographics, antiretroviral treatment history and the pres-
ence of any pre-treatment drug resistance mutations, as de-
fined by the International AIDS Society guidelines (IAS-
USA table, October 2006) [13]. 
  To evaluate the evolution of NRTI and NNRTI resistance 
mutations in the setting of virologic breakthrough, genotypic 
drug resistance testing was done using the VirtualPheno-
type
TM Assay, VIRCO Lab, Mechelen, Belgium. Genotypic 
resistance tests were performed at baseline and at the time of 
each confirmed virologic breakthrough (viral load >400 cop-
ies/mL). In cases where genotypic testing was not done pre-
viously, frozen plasma samples were available for retrospec-
tive testing. The rates of accumulation of individual and mul-
tiple NRTI and NNRTI resistance mutations were calculated 
in patients failing NNRTI-based therapy. In addition, the 
rates of acquisition of NRTI and NNRTI resistance muta-
tions were compared in patients with and without mutation 
135 at baseline. 
  Tests for independence between two discrete variables 
were done using the 
2 or Fisher’s exact test, as appropriate. 
Continuous variables were assessed using either Student’s t-
test (age) or the Mann-Whitney test (absolute and change 
from baseline in CD4 cell count). All reported p-values were 
two-sided, and p-values below a significance level of 0.05 
were considered statistically significant. 
RESULTS 
  The study included a total of 68 patients identified from a 
retrospectively collected database of IDUs who received 
NNRTIs for the first time and for more than 1 month and 
who had pre- and post-treatment genotypic resistance testing. 
At baseline, 30 patients (19 male) were identified as having a 
mutation at RT codon I135 [135T (17), 135V (7), 135M (3), 
135R (2), 135L (1)] while 38 patients (25 male) had no mu-
tations at codon 135. All patients carried subtype B virus. 
Median baseline CD4 cell counts and plasma viral loads 
were 190 cells/mm
3, 81,350 copies/mL and 190 cells/mm
3 
(p-value=0.99), 65,800 copies/mL (p-value=0.44) in the two 
groups, respectively. Twenty-three patients received nevirap-
ine, 6 received efavirenz and 1 received delavirdine in the 
first group, while 32 patients received nevirapine, 5 received 
efavirenz and 1 patient received delavirdine in the second 
group. In all cases, the agent of interest was given along with 
2 NRTIs and/or protease inhibitors to constitute a HAART 
regimen. The NRTIs commonly used included lamivudine 
(n=25 and 32) and didanosine (n=24 and 32) in patients with 
and without baseline mutations at codon 135, respectively. 
Other NRTIs, including stavudine, zidovudine and tenofovir, 
Table 1.  Baseline Patient Characteristics 
 
   With Baseline 135 Mutation  Without Baseline 135 Mutation  p-Value 
N 
Gender 
     Male (%) 
     Female (%) 
Age (years) 
     Mean 
     SD  
CD4 (cells/mm
3) 
     Median 
     Q1 – Q3 
Viral load (copies/mL) 
     Median 
     Q1 – Q3 
Follow-up period (months) 
     Median 
     Q1 – Q3 
Regimen based on 
     Nevirapine (%) 
     Efavirenz (%) 
     Delavirdine (%) 
 
RT mutations (%) 
 
Naïve to antiretrovirals (%) 
30 
 
19 (63%) 
11 (37%) 
 
45.7 
9.4 
 
190 
130 - 270 
 
81,350 
32,700 - >100,000 
 
15.7 
5.0-37.2 
 
23 (77%) 
6 (20%) 
1 (3%) 
 
3 (10%) 
 
14 (47%) 
38 
 
25 (66%) 
13 (34%) 
 
39.2 
7.1 
 
190 
110 - 270 
 
65,800 
26,780 - >100,000 
 
14.2 
5.4-21.6 
 
32 (84%) 
5 (13%) 
1 (3%) 
 
3 (8%) 
 
21 (55%) 
 
 
0.99 
 
 
0.003 
 
 
0.99 
 
 
0.44 
 
 
0.50 
 
 
0.76 
 
 
 
0.99 
 
0.63 
Note: Q1 indicates first quartile; Q3 third interquartile; RT indicates reverse transcriptase; SD indicates standard deviation. 10    The Open Virology Journal, 2007, Volume 1  Tossonian et al. 
were used as part of HAART in the remaining few patients 
with equal distribution in the two study groups. PIs were 
used in 7 regimens only including lopinavir, sequinavir, 
nelfinavir and indinavir. The baseline characteristics of study 
patients are presented in Table 1. 
  At a median follow-up period of 15 months, the median 
changes in CD4 cell counts were +135 cells/mm
3 and +90 
cells/mm
3 (p=0.32) while the CD4 cell counts were 300 
cells/mm
3 and 345 cells/mm
3 (p=0.84) in patients with and 
without baseline mutations at codon 135, respectively (Fig. 
1). Virologic suppression (HIV RNA <400 copies/mL) was 
achieved in 16/30 (53%) of patients having mutations at 
codon 135 at baseline and 16/38 (42%) in patients without 
baseline mutations at codon 135 (p=0.50) (Fig. 2). 
  As seen in Table 2, of those not suppressed with a baseline 
codon 135 mutation, 10/14 (71%) had NNRTI resistance mu-
tations [K103N (6), Y181C (3), G190A (2), V108I (1)] and 
4/14 (29%) had NRTI resistance [M184I/V (3), L74V (2), 
thymidine analogue mutations (TAMs) (2)]. In patients with 
no such mutation, 16/22 (73%) had NNRTI resistance [K103N 
(10), Y181C (9), G190A (7), V108I (2), L100I (1), V106M 
(1), Y188C (1)] and 12/22 (55%) had NRTI resistance 
[M184I/V (12), L74V (3), TAMs (1)] (p > 0.05 for all com-
parisons). In patients who experienced a virologic break-
through and had a baseline mutation at codon 135, 8/14 (57%) 
evolved a single NNRTI resistance mutation, a finding that 
was observed in only 4/22 (18%) patients who did not have 
such a baseline mutation (p = 0.029). The latter group was 
more likely to evolve multiple mutations (12/22 [55%] cases), 
a finding that was much less frequently observed (2/12 [14%] 
cases) in the setting of a 135 mutation at baseline (p = 0.033). 
DISCUSSION AND CONCLUSION 
  The virologic impact of mutations at codon 135 is not 
clear despite the fact that such mutations are extremely 
common. It is likely that mutations at RT codon 135 affect 
NNRTI susceptibility by virtue of their proximity, in the p51 
component of the RT dimer, to the NNRTI binding site [14]. 
The  7-8-loop (residues 132-140) in the p51 subunit of 
HIV RT contributes to the formation of the base of NNRTI- 
binding pocket. In one study, mutations at codons 132, 135 
and 138 in the 51 subunit of RT conferred high-level resis-
tance to nevirapine and delavirdine and low level resistance 
to efavirenz [15]. Position 135 of HIV RT is known as the 
anchor position of the HLA-B51 restricted cytotoxic T lym-
phocyte (CTL) responses [16]. CTL escape mutations occur 
at critical sites within HLA-restricted CTL epitopes where an 
amino acid substitution may abrogate epitope-HLA binding, 
reduce T-cell receptor recognition, or generate antagonistic 
CTL responses [17]. According to Mallal et al., a strong as-
sociation was observed between HLA-B51 and the presence 
of mutations at codon 135 of RT. In particular, all individu-
als with HLA-B51 had an I to T (79%) or V (21%) mutation 
at position 135 suggesting that non-synonymous mutations at 
position 135 of RT may lead to viral escape from host CTL 
responses [18]. Other studies; however, have associated 
HLA-B51 with slow progression to AIDS [19]. Thus, the 
explanation for the differences in the number of mutations 
observed in our study may be secondary to differential repre-
sentation of MHC alleles in both study groups. We plan to 
undertake the appropriate evaluations in our cohort to deter-
mine whether MHC variations provide a unifying explana-
tion for our observations. 
  Mutations at RT codon 135 are not widely recognized as 
associated with more classical NNRTI-resistance mutations 
and their clinical implications are unclear. Brown et al. 
found that the amino acid site 135 of RT was associated with 
reduced susceptibility to both nevirapine and delavirdine [5]. 
Vavro  et al. reported that a decreased susceptibility to 
efavirenz and nevirapine at baseline was seen in viruses with 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Median CD4 cell counts and median increases in CD4 cell counts at the latest follow-up visit in patients with and without baseline 
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mutations at codon 135 in antiretroviral naïve patients [8]. In 
addition, they showed that mutations at codon 135 at base-
line were associated with the accumulation of NNRTI-
resistance mutations [8]. Harrigan et al.; however, found no 
relationship between the presence of mutations at codon 135 
and virologic response [9]. In agreement with previous re-
ports, we did not detect significant differences in immu-
nologic or virologic responses in patients on NNRTI-based 
HAART as a function of the baseline genotype at codon 135. 
Further, such mutations at baseline were not significantly 
associated with the development or accumulation of NNRTI 
mutations while on therapy in the setting of loss of virologic 
suppression. Nevertheless, if resistance occurred, patients 
who had baseline 135 mutations were more likely to evolve 
single NNRTI resistance mutations (8/14 vs 4/22, p=0.029) 
which is in agreement with results from previous studies [8]. 
However, patients who had baseline 135 mutations were less 
likely to evolve multiple NNRTI resistance mutations (2/14 
vs 12/22, p=0.033) and possibly some NRTI mutations such 
as the M184V (3/14 vs 12/22, p=0.08). This contrasts with 
previous reports which suggested that the presence of base-
line mutations at codon 135 may accelerate the accumulation 
of more classical NNRTI resistance mutations. It should be 
emphasized that much of these data were generated with 
non-subtype B strains of HIV. This may explain why, in 
populations infected with subtype B virus, very different 
results may be obtained [8, 20]. 
  Although it is difficult to attribute all the mutations we 
observed to NNRTI treatment, it is generally agreed that 
NRTIs do not affect the evolution of NNRTI-associated mu-
tations or mutations selected by non-reverse transcriptase 
inhibitors. However, one recent publication reports some 
intriguing associations between NNRTI and NRTI muta-
tions. Cane et al. identified 24 accessory RT codon muta-
tions, including mutations at codon 135, as significantly as-
sociated with the accumulation of TAMs [21]. In our study, 
we did not find a significant association between mutations 
at codon 135 and TAMs, however, most of our patients were 
not on HAART regimens containing stavudine or zidovudine 
nor did they have complex resistance patterns including 
TAMs. Outside of this context, we are not aware of any re-
ports of NRTIs selecting for or associated with mutations at 
codon 135. In the absence of any evidence to the contrary, 
we must conclude that the patterns of genetic change we 
have observed are associated with NNRTI use. 
  One important implication of our results relates to the 
possible sequencing of NNRTIs in clinical practice, with the 
availability of second generation agents in this class. It may 
be that in patients with baseline mutations at codon 135, 
NNRTI resistance may be associated with the development 
of a single additional mutation, increasing the likelihood of 
agents such as etravirine remaining effective. This would not 
be the case if multiple NNRTI mutations were to develop, a 
situation that may be more likely with subtype B virus wild 
type at the 135 codon of RT. 
  The study has several limitations. First, it was conducted 
in a relatively small number of patients. Second, the study 
was done on IDUs enrolled in a DOT program and thus, the 
results might not be generalized to non-IDU populations or 
non-DOT settings. Third, resistance mutations considered 
where only those based on the IAS-USA guidelines and 
some other crucial or unknown mutations might not have 
been properly evaluated including minor mutations such as 
L283I. According to Brown et al., this can lead to further 
decrease in susceptibility to NNRTIs in the context of a pre-
existing 135 mutation [5]. Fourth, our study did not account 
for the effect of the different amino acid positions at codon 
135 as some specific mutations might be more important 
than others. Fifth, phenotypic assays were not done, without 
which it is hard to know surely whether the observed muta-
tions had any effect on the sensitivity or resistance to 
NNRTIs. Historically, however, and in the bulk virtual phe-
notypes performed in our centre, mutations at codon 135 
were associated with a 1.2-1.3-fold decrease in NNRTI sus-
ceptibility, suggesting a minimal effect on the efficacy of 
agents in this class as a result of this mutation alone. 
  In conclusion, our results indicate no significant differ-
ences in CD4 cell counts and HIV plasma viral load re-
sponses to NNRTI-based regimens as a function of baseline 
135 genotype. However, in patients with baseline mutations 
at codon 135 and experiencing virologic breakthrough, there 
were more evolution of single and less evolution of multiple 
NNRTI resistance mutations. This may have important im-
plications with respect to the initial selection of patients to 
receive NNRTI-based therapy at baseline with a view to se-
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quencing NNRTIs using newer agents in this class in subse-
quent courses of therapy. 
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